The UK and US have finalized a major commercial pact that will guarantee zero levies on UK pharmaceutical products being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to raise spending on medicines through the public health system. This move ensures that tariffs on these key exports will stay at zero for a period of 36 months.
This deal is in response to earlier threats to dramatically increase tariffs on branded drug products, with increases floated up to 100%.
"This agreement between the Britain reinforces the global environment for cutting-edge drugs and brings much-needed balance to U.S.–U.K. drug exports," a statement said.
Economic Impact
Drugs constitute one of the Britain's largest exports to the America, which is by far the largest market for leading companies like GSK and AstraZeneca.
Trade data show that in the year to the end of September, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This amount represented a significant portion of total UK exports in that span.
"This agreement secures work, boosts funding and sets the stage for the UK to become a worldwide center for life sciences," the Business and Trade Secretary stated.
Key British Pledges
The pact entails several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to double overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. In the past, rebates were more than twenty percent.
Recent Tensions
This agreement comes amid a protracted row between the pharmaceutical industry and the ministers over medicine costs and approval rates.
The disagreement were heightened by arguments that American consumers were charged a premium for the same drugs than consumers in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar investments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS had to spend more on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the last ten years.
